Literature DB >> 2759492

Geographic differences in digoxin inactivation, a metabolic activity of the human anaerobic gut flora.

V I Mathan1, J Wiederman, J F Dobkin, J Lindenbaum.   

Abstract

The inactivation of digoxin by conversion to reduced metabolites (digoxin reduction products, or DRP), a function of the anaerobic gut flora, was studied in normal volunteers from southern India and the United States. Digoxin was metabolised to DRP by 28 (13.7%) of 204 healthy south Indians in contrast to 67 (36.0%) of 186 New Yorkers (p less than 1 X 10(-6)). Only 1.0% of Indians compared with 14.0% of Americans excreted large amounts of metabolites (greater than 40% DRP) in the urine (p less than 1 X 10(-5)). Of 104 urban Indians, 23 (22.1%) were metabolisers, in contrast with five of 100 rural villagers (p less than 0.001). Within the urban group, digoxin metabolism correlated with education, frequency of animal protein intake, and most significantly, personal income. Organisms capable of reducing digoxin in vitro were found with similar frequencies in stool cultures from Indians and Americans. In the cultures of some subjects, DRP production was inhibited at lower dilutions but expressed at higher dilutions. We conclude that variations in drug metabolism between population groups may result from differences in the metabolic activity of the anaerobic gut flora probably mediated by environmentally determined factors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2759492      PMCID: PMC1434295          DOI: 10.1136/gut.30.7.971

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  21 in total

1.  Decreased digoxin cardioinactive-reduced metabolites after administration as an encapsulated liquid concentrate.

Authors:  D G Rund; J Lindenbaum; J F Dobkin; V P Butler; J R Saha
Journal:  Clin Pharmacol Ther       Date:  1983-12       Impact factor: 6.875

Review 2.  Intestinal flora in health and disease.

Authors:  G L Simon; S L Gorbach
Journal:  Gastroenterology       Date:  1984-01       Impact factor: 22.682

3.  Urinary excretion of reduced metabolites of digoxin.

Authors:  J Lindenbaum; D Tse-Eng; V P Butler; D G Rund
Journal:  Am J Med       Date:  1981-07       Impact factor: 4.965

4.  Diet and the faecal microflora of infants, children and adults in rural Nigeria and urban U.K.

Authors:  A M Tomkins; A K Bradley; S Oswald; B S Drasar
Journal:  J Hyg (Lond)       Date:  1981-06

5.  The development and application of a radioimmunoassay for dihydrodigoxin, a digoxin metabolite.

Authors:  V P Butler; D Tse-Eng; J Lindenbraum; S M Kalman; J J Preibisz; D G Rund; P S Wissel
Journal:  J Pharmacol Exp Ther       Date:  1982-04       Impact factor: 4.030

6.  Inactivation of digoxin by the gut flora: reversal by antibiotic therapy.

Authors:  J Lindenbaum; D G Rund; V P Butler; D Tse-Eng; J R Saha
Journal:  N Engl J Med       Date:  1981-10-01       Impact factor: 91.245

7.  Digoxin metabolism in patients.

Authors:  U Peters; L C Falk; S M Kalman
Journal:  Arch Intern Med       Date:  1978-07

8.  Digoxin-inactivating bacteria: identification in human gut flora.

Authors:  J R Saha; V P Butler; H C Neu; J Lindenbaum
Journal:  Science       Date:  1983-04-15       Impact factor: 47.728

9.  Reduction of digoxin to 20R-dihydrodigoxin by cultures of Eubacterium lentum.

Authors:  L W Robertson; A Chandrasekaran; R H Reuning; J Hui; B D Rawal
Journal:  Appl Environ Microbiol       Date:  1986-06       Impact factor: 4.792

10.  Inactivation of digoxin by Eubacterium lentum, an anaerobe of the human gut flora.

Authors:  J F Dobkin; J R Saha; V P Butler; H C Neu; J Lindenbaum
Journal:  Trans Assoc Am Physicians       Date:  1982
View more
  19 in total

Review 1.  Intestinal microbiome and digoxin inactivation: meal plan for digoxin users?

Authors:  Lingeng Lu; Yixing Wu; Lingjun Zuo; Xingguang Luo; Peter J Large
Journal:  World J Microbiol Biotechnol       Date:  2013-10-09       Impact factor: 3.312

2.  Drugs, bugs, and personalized medicine: pharmacometabonomics enters the ring.

Authors:  Ian D Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-19       Impact factor: 11.205

Review 3.  The intestinal microbiome and surgical disease.

Authors:  Monika A Krezalek; Kinga B Skowron; Kristina L Guyton; Baddr Shakhsheer; Sanjiv Hyoju; John C Alverdy
Journal:  Curr Probl Surg       Date:  2016-06-14       Impact factor: 1.909

Review 4.  Gut microbiome interactions with drug metabolism, efficacy, and toxicity.

Authors:  Ian D Wilson; Jeremy K Nicholson
Journal:  Transl Res       Date:  2016-08-13       Impact factor: 7.012

5.  The metabolism of drugs by the gut flora.

Authors:  M Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1994 Jul-Sep       Impact factor: 2.441

Review 6.  Age-related changes in the gastrointestinal system. Effects on drug therapy.

Authors:  F L Iber; P A Murphy; E S Connor
Journal:  Drugs Aging       Date:  1994-07       Impact factor: 3.923

Review 7.  Pharmacomicrobiomics: the impact of human microbiome variations on systems pharmacology and personalized therapeutics.

Authors:  Marwa ElRakaiby; Bas E Dutilh; Mariam R Rizkallah; Annemarie Boleij; Jason N Cole; Ramy K Aziz
Journal:  OMICS       Date:  2014-05-02

Review 8.  The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism.

Authors:  Peter Spanogiannopoulos; Elizabeth N Bess; Rachel N Carmody; Peter J Turnbaugh
Journal:  Nat Rev Microbiol       Date:  2016-03-14       Impact factor: 60.633

9.  Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta.

Authors:  Henry J Haiser; David B Gootenberg; Kelly Chatman; Gopal Sirasani; Emily P Balskus; Peter J Turnbaugh
Journal:  Science       Date:  2013-07-19       Impact factor: 47.728

Review 10.  Pharmacological Efficacy/Toxicity of Drugs: A Comprehensive Update About the Dynamic Interplay of Microbes.

Authors:  Juan Antonio Gimenez-Bastida; Lucia Martinez Carreras; Angela Moya-Pérez; José Moisés Laparra Llopis
Journal:  J Pharm Sci       Date:  2017-10-26       Impact factor: 3.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.